sclerostin


Also found in: Acronyms, Wikipedia.

sclerostin

A glycoprotein secreted by osteocytes that has anti-anabolic effects on bone. It has a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists.

Molecular pathology
Sclerostin is misregulated in van Buchem disease, which is characterised by increased bone mass.
References in periodicals archive ?
The Wnt inhibitors sclerostin (Figure 3E) and DKK1 (Figure 3F) were induced in Pb-exposed mice compared with controls, but HFD antagonized this effect although not significantly.
Serum FGF-23 levels (Human FGF-23 ELISA kit using monoclonal antibodies to the full FGF-23 molecule), Klotho (Human alpha-K1 ELISA using anti-Klotho antibodies) and sclerostin (Human Sclerostin ELISA kit) were applied in these patients.
Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Likely we'll use sclerostin therapy for a relatively short time--6 months, 12 months--followed by another drug, like an antiresorptive drug, and then attempt to take advantage of that first burst of anabolic activity again," he said.
It seems unlikely that we'll simply identify patients in need of skeletal restoration and add a sclerostin therapy and treat them until they don't have osteoporosis anymore.
Sclerostin and Dickkopf--1 as therapeutic targets in bone disease.
Measurement of Serum Sclerostin by an Enzyme-Linked Sandwich Assay in Sost Wild type and Knock-out Mice
Found in osteocytes, Sclerostin works its chemical magic by interfering with a process known as Wnt signaling, which helps regulate bone creation.
NASA's Commercial Biomedical Test Module (CBTM-3) experiment will examine whether the use of an antibody that blocks the action of the protein sclerostin can lead to gains in bone mass and thereby prevent skeletal deterioration.
The experiment will assess the effect of a sclerostin antibody on the loss of bone during space flights, the Belgian company said on Wednesday.
Interviewed Thought Leaders Consider Sclerostin Inhibitors the Most Exciting Agents that Will Emerge Over the Next Ten Years, According to Findings from Decision Resources